Oramed

{{Infobox company | name = Oramed Pharmaceuticals Inc. | logo = Oramed logo 2022.svg | caption = | trading_name =  | native_name =  | native_name_lang =  | romanized = | former type = | type = Public | traded_as = {{Nasdaq|ORMP}}<br />Russell Microcap Index component <br/>{{TLV|ORMP}} | industry = Biotech | fate = | predecessor = | successor = | foundation = {{Start date and age|2006}} | founder = | defunct =  | location_city = Jerusalem | location_country = | locations =  | area_served = | key_people = Nadav Kidron (CEO) | products = | production = | services = | revenue = | operating_income = | net_income = | assets = | equity = | owner = | num_employees = | parent = | divisions = | subsid = | homepage = {{URL|oramed.com}} | footnotes = | intl = | bodystyle = }}

'''Oramed Pharmaceuticals Inc.''' ({{Langx|he|אורמד}}), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.

== History == Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.<ref>{{cite news|last=Weinreb|first=Gali|title=Insulin pill co Oramed jumps on Nasdaq listing plans|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000814732&fid=1725|accessdate=16 February 2013|newspaper=Globes|date=15 January 2013}}</ref><ref>{{cite web|last=Blackburn|first=Nicky|title=Israeli patent moves closer to achieving oral insulin treatment|url=http://israel21c.org/health/israeli-patent-moves-closer-to-achieving-oral-insulin-treatment/|publisher=Israel21c|accessdate=16 February 2013|date=24 June 2007}}</ref>

== Product pipeline == Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.

In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.<ref>{{Cite web |last=Leichman |first=Abigail Klein |date=2013-02-12 |title=Groundbreaking insulin pill nearing market |url=https://www.israel21c.org/groundbreaking-insulin-pill-nearing-market/ |access-date=2025-05-08 |website=ISRAEL21c |language=en-US}}</ref><ref name=":0" /><ref>{{Cite web |title=Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2 |url=https://mayafiles.tase.co.il/rpdf/1138001-1139000/P1138037-00.pdf |website=mayafiles.tase.co.il}}</ref>

In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.<ref>{{Cite web |date=2021-08-17 |title=Israel developing injectable and oral vaccines as COVID cases soar |url=https://www.mobihealthnews.com/news/emea/israel-developing-injectable-and-oral-vaccines-covid-cases-soar |access-date=2025-05-08 |website=MobiHealthNews |language=en}}</ref><ref>{{Cite web |date=2021-07-22 |title=Israel to become first in world to test Oravax oral COVID-19 vaccine |url=https://www.jpost.com/health-science/israel-to-become-first-in-world-to-test-oral-covid-19-vaccine-674563 |access-date=2025-05-08 |website=The Jerusalem Post |language=en |issn=0792-822X}}</ref>

In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge.<ref>{{cite news|url=https://en.globes.co.il/en/article-oramed-plunges-after-reporting-trial-failure-1001435437|title=Oramed plunges after reporting trial failure|publisher=Globes|access-date=4 May 2023}}</ref> The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset. <ref name=":0">{{cite news|url=https://www.clinicaltrialsarena.com/news/oramed-diabetes-oral-insulin-pivotal-trial/?cf-view |title=Oramed to reinitiate pivotal type 2 diabetes trial after Phase III flop |website=clinicaltrialsarena.com |date=2024-02-21 |access-date=2025-05-03}}</ref>

In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.<ref>{{cite news |last=Serafino |first=Phil |last2=Odenheimer |first2=Alisa |date=2 May 2023 |title=Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company |url=https://www.bloomberg.com/news/articles/2023-05-02/conservative-pundit-shapiro-takes-stake-in-israeli-drug-company?leadSource=uverify%20wall&sref=xhJDrP3t |access-date=4 May 2023 |publisher=Bloomberg}}</ref>

On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.<ref name=":0" /><ref>{{Cite web |last=Pharmaceuticals |first=Oramed |date=2018-12-13 |title=Oral Insulin Moves Towards Becoming Reality in U.S., China |url=https://www.globaltrademag.com/oral-insulin-moves-towards-becoming-reality-in-u-s-china/ |access-date=2025-05-08 |website=Global Trade Magazine}}</ref>

== Subsidiaries ==

OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.

== References == {{Reflist}}

{{Israel NASDAQ}}{{TA 100 companies}} Category:Biotechnology companies of Israel Category:Companies listed on the Nasdaq Category:Pharmaceutical companies of Israel Category:Pharmaceutical companies established in 2006 Category:2006 establishments in Israel